Development of Sorafenib in Malignant Gliomas: Rationale and Early Clinical Experience
Pp. 162-170 (9)
Rachel Grossman and Jaishri Blakeley
Sorafenib is a multi-targeted receptor tyrosine kinase inhibitor (TKI), with activity against vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, VEGFR-3, Raf-1, B-Raf, C-Raf, and plateletderived growth factor receptor (PDGFR) -α and -β. Currently, sorafenib has regulatory approval for use in metastatic renal cell carcinoma and hepatocellular carcinoma. An attractive activity profile, pre-clinical evidence of antitumor activity in human malignant glioma models and a promising safety profile have led to recent phase I/II clinical trials for patients with malignant gliomas. Here we review the current data, and future directions for the development of sorafenib for malignant glioma.
Department of Neurosurgery and Neurology and Johns Hopkins School of Medicine, Baltimore, MD.